Representation of older patients in cancer treatment trials
Edward L. Trimble(Memorial Sloan Kettering Cancer Center), Boris Freidlin(Emmes (United States)), Dennis Cain(National Cancer Institute), Christine L. Carter(Emmes (United States)), Richard S. Ungerleider(Theradex Oncology (United States)), Michael Friedman(National Cancer Institute)
Cited by 349
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531
Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer Patients
|JNCI Journal of the National Cancer Institute|2006|415
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
|Biochemistry|1981|375
Representation of African-Americans, Hispanics, and Whites in National Cancer Institute Cancer Treatment Trials
|JNCI Journal of the National Cancer Institute|1996|275